Modeling undetected poliovirus circulation following the 2022 outbreak in the United States.

IF 5.5 3区 医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-01-04 DOI:10.1080/14760584.2023.2299401
Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson
{"title":"Modeling undetected poliovirus circulation following the 2022 outbreak in the United States.","authors":"Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson","doi":"10.1080/14760584.2023.2299401","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.</p><p><strong>Research design and methods: </strong>Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).</p><p><strong>Results: </strong>With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.</p><p><strong>Conclusions: </strong>In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284832/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2023.2299401","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.

Research design and methods: Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).

Results: With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.

Conclusions: In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2022 年美国爆发脊髓灰质炎疫情后未被发现的脊髓灰质炎病毒传播模型。
背景:纽约州(NYS)报告了一例脊髓灰质炎病例(2022 年 6 月)和输入性 2 型循环疫苗衍生脊髓灰质炎病毒(cVDPV2)疫情(最后一次阳性废水检测时间为 2023 年 2 月),目前仍存在未检测到的潜在传播的不确定性:我们对先前的确定性模型进行了扩展,采用成熟的随机建模方法来描述 cVDPV2 无传播(CNC)的置信度与最后一次检测到传播信号(即脊髓灰质炎病毒阳性急性弛缓性脊髓炎病例或废水样本)后时间的函数关系:由于监测范围覆盖了纽约州的大部分人口,且重点关注疫情爆发县,根据监测灵敏度和人口混合模式,建模结果表明在最后一次监测信号呈阳性后的 3-10 个月内 CNC(95%)较高。监测灵敏度的不确定性意味着需要更长的时间才能达到较高的 CNC:结论:在脊髓灰质炎灭活疫苗(IPV)免疫覆盖率较高的人群中,未接种疫苗的个体可能会出现罕见的脊髓灰质炎病例。模型分析表明,此类疫情不太可能重新形成地方性传播或导致大量麻痹病例。实现并保持 IPV 的高免疫覆盖率仍然是预防疫情爆发和缩短输入性脊髓灰质炎病毒传播持续时间的最有效措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Vaccines
Expert Review of Vaccines 医学-免疫学
CiteScore
9.10
自引率
3.20%
发文量
136
审稿时长
4-8 weeks
期刊介绍: Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
期刊最新文献
Hookworm vaccines: current and future directions. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. Estimating the time required to reach HPV vaccination targets across Europe. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024. Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1